Reply to thread

Conclusion 

Based on a BIO-PSA® AC 7-4302 silicone matrix, EA as an anastrozole solvent, and the use of glycerol as a crystallization inhibitor, a homogeneous drug wet mix was produced, capable of building up TDDS as ready-to-use formulation. This anastrozole drug-in-adhesive patch was found to be stable after drying and stored over months. In Franz diffusion cell experiments, a continuous anastrozole release profile, as well as permeation of 65% of TDDS drug loading within 48 h, was found, providing the basis for a proof of functioning study in an experimental TDDS exposure to animals. In vivo data showed a favorable plasma anastrozole concentration–time course following application of the final anastrozole transdermal system to beagle dogs, comparable to plasma concentrations 24–72 h following oral administration in humans. The study attests to the eligibility of the API anastrozole (drug) for transdermal application route and shows the feasibility of anastrozole TDDS in a proof of principle design, which demands expanded confirmatory animal studies, predicting the convenient alternative use of anastrozole to treat BC in women with expected better therapeutic index and patient compliance.